Monte Rosa Therapeutics, Inc. short interest in 2026
In 2026, Monte Rosa Therapeutics, Inc.'s disclosed short interest ran from 8.53% of shares outstanding on 15 Jan 2026 to 22.58% on 15 Sep 2026, a change of +14.05 percentage points. The year's high was 23.29% on 30 Jun 2026 and its low 8.53% on 15 Jan 2026, averaging 18.10% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 20.63 days on 15 May 2026. Full history: Monte Rosa Therapeutics, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 8.53% (15 Jan 2026)
- End of year
- 22.58% (15 Sep 2026)
- Change
- +14.05 pp
- High
- 23.29% (30 Jun 2026)
- Low
- 8.53% (15 Jan 2026)
- Average
- 18.10%
- Highest days to cover
- 20.63 (15 May 2026)
- SEC filings marked
- 6
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 8.53% | 1.37 | |
| 30 Jan 2026 | 11.77% | 6.73 | |
| 13 Feb 2026 | 14.33% | 9.28 | |
| 27 Feb 2026 | 15.53% | 10.70 | |
| 13 Mar 2026 | 13.70% | 12.64 | |
| 31 Mar 2026 | 16.75% | 8.81 | 10-K filed, results (8-K) |
| 15 Apr 2026 | 19.79% | 15.99 | |
| 30 Apr 2026 | 18.92% | 17.85 | |
| 15 May 2026 | 18.70% | 20.63 | 10-Q filed, results (8-K) |
| 29 May 2026 | 20.00% | 19.21 | |
| 15 Jun 2026 | 21.46% | 16.62 | |
| 30 Jun 2026 | 23.29% | 8.49 | |
| 15 Jul 2026 | 21.49% | 13.08 | |
| 31 Jul 2026 | 19.29% | 10.59 | |
| 14 Aug 2026 | 20.46% | 13.99 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 21.19% | 16.56 | |
| 15 Sep 2026 | 22.58% | 17.08 |
See also: Monte Rosa Therapeutics, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.